EUS-guided thrombin injection and coil implantation for gastric varices: feasibility, safety, and outcomes

Background and Aims: Gastric varices (GVs) are reported in up to 20% of patients with portal hypertension, and bleeding is often more severe and challenging than esophageal variceal bleeding. Data are limited on prophylaxis of GV bleeding or management in the acute setting, and different techniques are used. This study evaluated outcomes after EUS-guided placement of coils in combination with thrombin to manage GVs. Methods: We retrospectively reviewed all patients treated with combination EUS-guided therapy with coils and thrombin between October 2015 and February 2020. Results: Twenty patients underwent 33 procedures for GV therapy; 16 of 20 (80%) had type 1 isolated GVs and 4 patients had type 2 gastroesophageal varices. The median follow-up was 842 days (interquartile range [IQR], 483961). Seventeen patients (85%) had underlying cirrhosis, the most common etiologies being alcohol-related liver disease and nonalcoholic steatohepatitis. The median Child-Pugh score was 6 (IQR, 5-7). In 11 patients (55%), the indication was secondary prophylaxis to prevent recurrent bleeding; in 2 of 20 patients (10%), the bleeding was acute. Technical success was achieved in 19 patients (95%). During follow-up, the obliteration of fl ow within the varices was achieved in 17 patients (85%). The 6-week survival rate was 100%, and 2 adverse events, recurrent bleeding at day 5 and at day 37, were reported; both recurrent bleeding events were successfully managed endoscopically. Conclusions: EUS-guided GV obliteration combining coil placement with thrombin, in our experience, was technically safe with good medium-term efficacy. fi cacy. A multicenter randomized controlled trial comparing different treatment strategies is desirable to understand options better.